Sumatriptan succinate

• Description:

  Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research[1][2][3][4].

• Product Name Alternative:

  GR 43175 succinate

• UNSPSC:

  12352005

• Hazard Statement:

  H318

• Target:

  5-HT Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Sumatriptan-succinate.html

• Purity:

  99.89

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

• Smiles:

  O=C (O) CCC (O) =O.O=S (CC1=CC2=C (NC=C2CCN (C) C) C=C1) (NC) =O

• Molecular Formula:

  C18H27N3O6S

• Molecular Weight:

  413.49

• Precautions:

  H318

• References & Citations:

  [1]S J Peroutka, et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989 Apr 12;163 (1) :133-6. |[2]K L Dechant, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992 May;43 (5) :776-98. |[3]Razzaque Z, et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol. 1999 Jan;47 (1) :75-82.|[4]Bates EA, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010 Feb;30 (2) :170-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  5-HT1 Receptor; mLAG-3

• Citation 01:

  Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Headache Pain. 2024 Oct 30;25 (1) :187.|Mol Pharmacol. 2023 Nov;104 (5) :230-238.|Personalized Medicine Universe. 2019 May. |ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.

• CAS Number:

  103628-48-4